Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global proton pump inhibitors (PPIs) market size was valued at USD 3.2 billion in 2023, driven by the rising incidence of gastroesophageal reflux disease (GERD) cases across the globe. The market is expected to grow at a CAGR of 4.50% during the forecast period of 2024-2032, with the values likely to rise from USD 3.34 billion in 2024 to USD 4.76 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Proton pump inhibitors are medicines used to control the acid released through the glands in the lining of the stomach. They are used to relieve the symptoms of acid reflux or gastroesophageal reflux disease (GERD), along with treating stomach ulcers and damage to the lower esophagus caused by acid reflux. Omeprazole, Esomeprazole, and Lansoprazole are some of the most common types of proton pump inhibitors sold in the market.
In the historical period, the proton pump inhibitors (PPIs) market value has observed a significant upswing owing to the high accessibility and affordability of the drugs. The market is segmented into over-the-counter drugs and prescription drugs like Rabeprazole and Pantoprazole, among others. In addition, a rise in the prevalence of gastrointestinal disorders like peptic ulcers and GERD, especially driven by lifestyle and an aging population have driven the high market demand.
With a deeper understanding of human physiology, coupled with improving research and development infrastructure, health institutions have identified the potential risks of prolonged PPI usage which include kidney damage, osteoporosis, and infections. As a result, the proton pump inhibitors (PPIs) market growth has slowed down in recent years. There is immense focus on cautious prescribing practices along with rising development of generic and novel drugs. Along with novel drug formulations, non-pharmacological treatments are also emerging in the market, which are expected to affect the market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product Type
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The United States has held significant proton pump inhibitors (PPIs) market share in the historical period. The presence of key healthcare players which are continuously working to acquire smaller companies and drive innovation through improved research and development and expanding market reach is a vital factor. Moreover, the regulatory authorities like FDA closely monitor the safety profile of PPIs, their potential side effects and promoting quality distribution of the drugs.
Europe, being home to several influential healthcare and academic institutions, is contributing to fostering the proton pump inhibitors (PPIs) market demand in the region. With high prevalence of gastrointestinal diseases, especially in the geriatric population, makes the region a major market for PPIs.
The Asia Pacific region with rising development and improving healthcare infrastructure is expected to witness rapid growth in the forecast period. The region is experiencing several foreign investments from major healthcare companies, which are working on setting up research labs in the region. With such initiatives, they can leverage the area’s academic talent to develop novel drugs.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 3.2 billion in 2023, driven by the rising prevalence of GERD (gastroesophageal reflux disease) across the globe.
The market is anticipated to grow at a CAGR of 4.50% during the forecast period of 2024-2032, likely to reach a market value of USD 4.76 billion by 2032.
The high market demand is driven by the rising investments and development for novel drugs for treating gastrointestinal diseases.
As per the current market trend, the Asia Pacific region is expected to witness the growth of the market, on a contrary to the historic period, wherein North America experienced rapid growth.
The market can be broadly categorised based on drug type into OTC drugs and prescription drugs. OTC drugs are further divided into omeprazole, lansoprazole, and esomeprazole, among others, while prescription drugs are sub-divided into rabeprazole, dexlansoprazole, and pantoprazole.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Pfizer, Eisai Pharmaceuticals, Santarus, Inc, Wyeth, Janssen Pharmaceutical, Takeda Pharmaceutical Company Limited, Sanofi S.A., Teva Pharmaceuticals and Eli Lilly.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124